News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Almirall Seen Likely to Repeat Lung Drug Trial
October 14, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
MADRID, Oct 14 (Reuters) - Spanish pharmaceutical company Almirall is expected to announce on Wednesday that it will repeat clinical trials on its Aclidinium Bromide lung drug following a surprise setback last month, analysts said.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 3
Europe
MORE ON THIS TOPIC
Rare disease
Disc’s Regulatory Comeback Plan for Rejected Drug Relies on Old FDA Leadership
February 17, 2026
·
3 min read
·
Annalee Armstrong
Psychedelics
Compass’ Psychedelic Shows Durability ‘In-Spades’ as Path to FDA Clears
February 17, 2026
·
3 min read
·
Heather McKenzie
Immunology and inflammation
Ocular’s Hydrogel Beats Regeneron’s Eylea in Wet AMD Study, Plots Path to FDA
February 17, 2026
·
2 min read
·
Tristan Manalac
Podcast
As FDA Moves Away From Animal Testing, AI and Organoids Can Shine
February 17, 2026
·
1 min read
·
Jef Akst
